Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma episode artwork

EPISODE · Sep 9, 2022 · 57 MIN

Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

from MIB Agents OsteoBites and osTEAo · host MIB Agents Osteosarcoma

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions. --- Dr. Nathalie Gaspar, MD, PhD, is a pediatric oncologist at Gustave Roussy Cancer Campus (Villejuif, France), head of the adolescent and young adult (AYA) unit and chair of the AYA program of the institute (SPIAJA program), since 2009. She is in charge of bone sarcomas, cancers with peak incidence in the AYA population, from biology to clinical care. Dr Gaspar is also pediatric head of the French bone adult and pediatric sarcoma group, GROUPOS. She is actively involved in early new drug development in France and in Europe, through her participation to the clinical trial committee of the Innovative Therapeutics for Child and adolescent with Cancer (ITCC) consortium and through her action as co-chair of the Fostering Age Inclusive Research (FAIR) trial initiative of the multi-stakeholder ACCELERATE platform. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Episode metadata supplied by the publisher feed · Published Sep 9, 2022

Embed this episode

NOW PLAYING

Report on the Phase I/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

0:00 57:05

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MIB Agents OsteoBites and osTEAo?

This episode is 57 minutes long.

When was this MIB Agents OsteoBites and osTEAo episode published?

This episode was published on September 9, 2022.

Can I download this MIB Agents OsteoBites and osTEAo episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!